[1]
LuanP.V., TienN.D., HaiN.M., TienN.D. và DuyenT.T. 2021. Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations. Journal of 108 - Clinical Medicine and Phamarcy. 15, TA (tháng 4 2021). DOI:https://doi.org/10.52389/ydls.v15iTA.733.